Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 44Breast Neoplasms 42Lung Neoplasms 27Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 19Uterine Cervical Neoplasms 13Prostatic Neoplasms 13Ovarian Neoplasms 11Head and Neck Neoplasms 11Carcinoma, Hepatocellular 11Pancreatic Neoplasms 10Melanoma 10Brain Neoplasms 9Sarcoma 7Neoplastic Cells, Circulating 7Myelodysplastic Syndromes 7Glioma 7Esophageal Neoplasms 7Endometrial Neoplasms 7Multiple Myeloma 6Gastrointestinal Neoplasms 6Disease 6Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Uveal Melanoma 4Skin Neoplasms 4Neoplasm, Residual 4

Interventions

Valganciclovir 2letermovir 1Valacyclovir 1Therapeutics 1Polymerase Chain Reaction 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Cell Count 1Blood Specimen Collection 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytomegalovirus Infections × Blood Specimen Collection × 1 year × Clear all
NCT04017962 2025-08-11

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 13 charts

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡